Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Sunnybrook Health Sciences Centre | OTHER |
| British Columbia Cancer Agency | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare the toxicity of two new radiation schedules for the treatment of prostate cancer. Patients will be randomized to receive 5 treatments delivered every other day over 11 days, or once per week over 29 days. Both of these schedules are shorter than the standard treatment which is usually 39 treatments over 8 weeks.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Short treatment time (11 days) | Experimental |
| |
| Long treatment time (29 days) | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Image-guided radiotherapy | Radiation | 40 Gy / 5 fractions / 11 days |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Bowel related quality-of-life | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Gastrointestinal toxicity | Radiation Therapy Oncology Group Acute and Late Morbidity Scoring Schema | During radiotherapy, at 3 and 6 months, then every 6 months after |
| Genitourinary toxicity | Radiation Therapy Oncology Group Acute and Late Morbidity Scoring Schema |
Not provided
Inclusion Criteria:
Low or intermediate risk prostate cancer patients as defined by:
Age >= 18 years
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Aldrich Ong, MD | CancerCare Manitoba | Principal Investigator |
| Andrew Loblaw, MD | Sunnybrook Health Sciences Centre | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| BC Cancer Agency - Abbotsford Centre | Abbotsford British Columbia | British Columbia | V2S 0C2 | Canada | ||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40288917 | Derived | Ong WL, Quon H, Ong A, Cheung P, Chu W, Chung H, Vesprini D, Chowdhury A, Panjwani D, Alayed Y, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Kulasingham-Poon M, Mamedov A, Deabreu A, Loblaw A. Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body Radiotherapy. Eur Urol Oncol. 2025 Aug;8(4):909-913. doi: 10.1016/j.euo.2025.03.011. Epub 2025 Apr 26. | |
| 29551231 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D061089 | Radiotherapy, Image-Guided |
| ID | Term |
|---|---|
| D011878 | Radiotherapy |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Image-guided radiotherapy |
| Radiation |
40 Gy / 5 fractions / 29 days |
|
| During radiotherapy, at 3 and 6 months, then every 6 months after |
| PSA relapse rate | 3 and 5 years |
| Patient Overall Quality of life | During radiotherapy, at 3 and 6 months, then every 6 months after |
| Salvage androgen deprivation therapy rate | 3 and 5 years |
| CancerCare Manitoba |
| Winnipeg |
| Manitoba |
| R3E 0V9 |
| Canada |
| Sunnybrook Health Sciences Centre | Toronto | Ontario | M4N 3M5 | Canada |
| Derived |
| Quon HC, Ong A, Cheung P, Chu W, Chung HT, Vesprini D, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Loblaw A. Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial. Radiother Oncol. 2018 May;127(2):206-212. doi: 10.1016/j.radonc.2018.02.029. Epub 2018 Mar 15. |
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |